Immuno-oncology is the next big thing for big pharma! Now, biopharmaceutical companies such as $GTBP are making dramatic advances in an emerging area of research known as immuno-oncology. This marks a significant milestone in the battle against cancer. As the name implies, immuno-oncology marshals the human body’s own immune system to fight cancer. In many cases, immunotherapy is vastly preferable to conventional treatments. Survival rates are higher in several tumor types, and these medications have the potential to significantly extend lives. Treatments also can be deployed against a wide array of cancers. I believe immuno-oncology holds enormous promise for patients and significant opportunities for investors.
Market Data 
Markets 
AI
